MutationForecaster® (mutationforecaster.com) is Cytognomix’s patented web-portal for analysis of all types of mutations – coding and non-coding- including interpretation, comparison and management of genetic variant data. It’s a fully automated genome interpretation solution for research, translational and clinical labs.
Run our world-leading genome interpretation software on your exome, gene panel, or complete genome (Shannon transcription factor and splicing pipelines, ASSEDA, Veridical) with the Cytognomix User Variation Database and Variant Effect Predictor. With our integrated suite of software products, analyze coding, non-coding, and copy number variants, and compare new results with existing or your own database. Select predicted mutations by phenotype using articles with CytoVisualization Analytics. With Workflows, automatically perform end-to-end analysis with all of our software products. Download an 1 page overview of MutationForecaster® (link)
Subscribe and analyze your own data via the cloud or… Don’t want to run your own analyses on MutationForecaster®? Let us do it for you with our Bespoke Analysis Service.
Experience our suite of genome interpretation products through a free trial of MutationForecaster®. Once you register, we provide datasets from our peer-reviewed publications to evaluate these software tools.
Automated radiation biodosimetry
Ionizing radiation produces characteristic chromosome changes. The altered chromosomes are known as dicentric chromosomes [DCs]). DC biodosimetry is approved by the IAEA for occupational radiation exposure, radiation emergencies, or monitoring long term exposures. The DC assay can also monitor effects of interventional radiation therapies.
Cytognomix has developed a novel approach to find DCs (TBME). The Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) software works on multiple platforms and uses images produced by any of the existing automated metaphase capture systems found in most cytogenetic laboratories. ADCI is now available for for trial or purchase (link). Or contact us for details (pricing).
ADCI* uses machine learning to distinguish monocentric and dicentric chromosomes (Try the Dicentric Chromosome Identifier web app). With novel image segmentation, ADCI has become a fully functional cytogenetic biodosimetry system. ADCI takes images from metaphase scanning systems, selects high quality cells, identifies dicentric chromosomes, builds biodosimetry calibration curves, and estimates exposures. ADCI fulfills the criteria established by the IAEA for accurate triage biodosimetry of a sample in less than an hour. The accuracy is comparable to an experienced cytogeneticist. Check out our online user manual: wiki.
We find and validate mutations and gene signatures that others cannot with advanced, patented genomic bioinformatic technologies. Cytognomix continues our long track record of creating technologies for genomic medicine. We anticipate and implement the needs of the molecular medicine and genomics communities.
Predict chemotherapy outcomes
Pharmacogenomic responses to chemotherapy drugs can be predicted by supervised machine learning of expression and copy number of relevant gene combinations. Since 2015, CytoGnomix has used biochemical evidence to derive gene signatures from changes in gene expression in cell lines, which can subsequently be examined in patients that have been treated with the same drugs. We have derived signatures for 30 different commonly used drugs. Try out out our online predictor: https://chemotherapy.cytognomix.com.
Quantifying responses to ionizing radiation with gene expression signatures.
Gene signatures derived by machine learning have low error rates in externally validated, independent radiation exposed data. They exhibit high specificity and granularity for dose estimation in humans and mice. These signatures can be designed to avoid the effects of confounding, comorbidities which can reduce specificity for detecting radiation exposures. See: https://f1000research.com/articles/7-233/v2
Single copy genomic technologies
- Customized genomic microarrays
- Ultrahigh resolution FISH probes (article):
- Microarray-based comparative genomic hybridization (aCGH) can use SC technology to increase reproducibility and reduce cost per sample.
December 29, 2020. Coming soon… ADCI_Online
Greetings to you for a safe and healthy New Year. The Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) has become the biodosimetry industry’s leading software system for accurate and rapid quantification of absorbed ionizing radiation. This year we upgraded our Windows-based system to also determine partial body exposures, both fraction of cells exposed and […]
Dec. 10, 2020. New article on chemotherapy response prediction
We have published: Pathway‐extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors. Ashis J. Bagchee‐Clark , Eliseos J. Mucaki, Tyson Whitehead, and Peter K. Rogan MedComm (Wiley) 1(3): 311-327, 2020. (https://doi.org/10.1002/mco2.46) Abstract: Cancer chemotherapy responses have been related to multiple pharmacogenetic biomarkers, often for the same drug. This […]
Nov. 9, 2020. Notice of Allowance for US Pat App. Ser. No. 16/057,710
CytoGnomix’s Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) system will be awarded a US Patent for all claims covering “Smart Microscope System for Radiation Biodosimetry.” The patent application is available at: https://patents.google.com/patent/US20200050831A1 The abstract reads: An automated microscope system is described that detects dicentric chromosomes (DCs) in metaphase cells arising from exposure to ionizing […]
New support for geostatistical analysis of COVID19 hotspots in Ontario
In response to the Call for Proposals under its Innovation for Defence Excellence and Security (IDEaS) program to address COVID-19 challenges, the Department of National Defence has recommended CytoGnomix’s project: Locating emerging COVID19 hotspots in Ontario after community transmission by time-correlated, geostatistical analysis for funding following evaluation against mandatory, point rated criteria, and strategic considerations. […]
September 4, 2020. New article on automated partial body radiation exposure determination
We have added the capability to determine whether samples exposed to ionizing radiation are wholly or partially irradiated. If partially, the approach determines the fraction of metaphase cells exposed and the whole body-equivalent dose completely automatically. CytoGnomix’s Automated Dicentric Chromosome Identifier and Dose Estimation software has been upgraded to generate these results as part of […]
August 31, 2020. Presentation on molecular mechanism of severe riboviral infections at the RiboClub Forum 2020
Aug. 31, 2020. Presentation at the 2020 American Society of Human Genetics meeting
We are giving a platform presentation at the upcoming American Society of Human Genetics virtual meeting #ASHG2020 Session: Personalized Medicine Approaches in Healthcare. Paper: Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of responses to kinase inhibitors P. K. Rogan(1,2), A. J. Bagchee-Clark(1), E. J. Mucaki(1). 1. Department of Biochemistry, University of Western […]
August 14, 2020. Interview on Scientific Sense podcast
Peter Rogan was interviewed by Gill Eapin for his daily podcast, Scientific Sense, focused on Science & Economics about our research projects about COVID19. Listen at the link below. https://anchor.fm/scientificsense/episodes/Prof–Peter-Rogan–Professor-of-Biochemistry-and-Biostatistics-at-Western-University-ei5i40 #medicine #sarscov2 #covidー19 #medicalsciences #epidemiology #health #geostatistics #hotspots #publichealth #genomics #molecularmechanism